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(GR) antagonist Org 34850 on fast and delayed inhibition of
corticosterone secretion in response to the synthetic
glucocorticoid methylprednisolone (MPL). Male rats were
implanted with a catheter in the right jugular vein, for blood
sampling and MPL administration, and with an s.c. cannula
for Org 34850 administration. All experiments were
conducted at the diurnal hormonal peak in the late afternoon.
Rats were connected to an automated sampling system and
blood samples were collected every 5 or 10 min. Org 34850
(10 mg/kg, s.c.) or vehicle (5% mulgofen in saline) wasJournal of Endocrinology (2008) 196, 323–330
0022–0795/08/0196–323 q 2008 Society for Endocrinology Printed in Greatinjected at 1630 h; 30 min later, rats received an injection of
MPL (500 mg/rat, i.v.) or saline (0.1 ml/rat). We found that
an acute administration of MPL rapidly decreased the basal
corticosterone secretion and this effect was not prevented by
acute pretreatment with Org 34850. However, blockade of
GR with Org 34850 prevented delayed inhibition of MPL on
corticosterone secretion measured between 4 and 12 h after
MPL administration. Our data suggest an involvement of GR
in modulating delayed, but not fast, inhibition induced by
MPL on basal corticosterone secretion.
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There is considerable evidence for the involvement of
dysfunction of the hypothalamic–pituitary–adrenal (HPA)
axis in the pathophysiology of stress related disorders.
Moreover, clinical evidence suggests that overactivity of the
HPA axis in depression (Dinan 1994) and chronic fatigue
syndrome (Demitrack et al. 1991) could be due to alterations
in the mechanisms through which glucocorticoids, secreted
by the adrenal cortex, exert inhibitory negative feedback
effects on the HPA axis (Dallman et al. 1987).
Based on the time of onset of glucocorticoid effects on
HPA axis activity, negative feedback has been divided into
three distinct time domains (Keller-Wood & Dallman 1984):
fast feedback, which occurs within seconds or minutes;
intermediate/early delayed feedback, which occurs within
2 h; and slow/late delayed feedback, which occurs within a
range of O2 h to days. The mechanism underlying delayed
feedback has been extensively investigated. It is clear that
delayed feedback is due to a genomic action of glucocorti-
coids, which is mediated through an interaction with two
different receptors: mineralocorticoid receptors (MRs) and
glucocorticoid receptors (GRs; Reul & De Kloet 1985, Reul
et al. 1987). How glucocorticoids mediate fast feedback,
however, remains unclear. Evidence suggests that rapid non-genomic glucocorticoid actions could be mediated by a
membrane receptor (Orchinik et al. 1991).
Fast feedback has been largely investigated using either in vitro
models ( Johnson et al. 1982, Widmaier & Dallman 1984,
bou-Samra et al. 1986, Dayanithi & Antoni 1989, Nicholson &
Gillham 1989) or in vivo either using rats under acute
stress conditions (Sayers & Sayers 1947, Gray & Munson
1951, Keller-Wood & Dallman 1984) or following cortico-
tropin-releasing factor (CRF)-induced adrenocorticotrophin
(ACTH) secretion (Hinz & Hirschelmann 2000). Fast feedback
has also been described in man, with investigation of ACTH
responses to glucocorticoid feedback in healthy subjects
(Krishnan et al. 1991, Posener et al. 1997, Boscaro et al. 1998)
and in depressed patients (Young et al. 1991, Juruena et al. 2006).
We have sought to investigate the role of GRs in mediating
negative feedback in unstressed animals utilising a GR
antagonist. We used the high-affinity GR antagonist Org
34850 (Bachmann et al. 2003, Peeters et al. 2004) to probe the
role of GR on the fast and delayed inhibition of corticosterone
secretion induced by the synthetic glucocorticoid methylpred-
nisolone (MPL). In contrast with previous studies in rats, where
either stress or CRH was used to induce ACTH and
corticosterone negative feedback, in this study glucocorticoids
negative feedback was investigated during the physiological
corticosterone circadian peak. We have recently shown thatDOI: 10.1677/JOE-07-0503
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no effect on corticosterone release in either basal or stress
conditions (Spiga et al. 2007). In the same study, we also showed
that the same dose of Org 34850 was able to antagonise the
inhibitory effect of MPL on stress-induced corticosterone
secretion. We have now been able to use our automated blood
sampling (ABS) system, which allows us to collect blood samples
every 5 or 10 min for a period of up to 15 h, to investigate
whether Org 34850 can inhibit the effect of MPL on the fast,
intermediate and delayed inhibition of endogenous cortico-
sterone secretion. Furthermore, this high-frequency sampling
procedure has also allowed us to investigate the effect of MPL
and Org 34850 on the pulsatile pattern of corticosterone release.Materials and Methods
Subjects
All experimentswere conducted on male adult Sprague–Dawley
rats (Harlan-Olac, Bicester, UK) weighing250–300 g at the time
of surgery. Animals were group-housed four in each cage and
allowed to acclimatise to the housing facility for a minimum of 1
week prior to the start of experiments. Rats were maintained
under standard environmental conditions (21G1 8C) under a
14 h light:10 h darkness schedule (lights on at 0515 h) and food
and water were provided ad libitum throughout the experiment.
All animal procedures were approved by the University of
Bristol Ethical Review Group and were conducted in
accordance with Home Office guidelines and the UK
Animals (Scientific Procedures) Act, 1986. All possible efforts
were made to minimise the number of animals used and their
suffering.Surgery and blood sampling
Animals were anaesthetised with a combination of Hypnorm
(0.32 mg/kg fentanyl citrate and 10 mg/kg fluanisone, i.m.;
Janssen Pharmaceuticals, Oxford, UK) and diazepam
(2.6 mg/kg i.p.; Phoenix Pharmaceuticals, Gloucester, UK).
The right jugular vein was exposed and a silastic-tipped
(i.d. 0.50 mm, o.d. 0.93 mm, Merck) polythene cannula
(Portex, Hythe, UK) was inserted into the vessel until it lay
close to the entrance of the right atrium. The cannula was
prefilled with pyrogen-free heparinised (10 IU/ml) isotonic
saline. During the same surgery, an s.c. cannula, for drug
administration, was inserted under the skin between the
shoulder blades. The free ends of both cannulae were
exteriorised through a scalp incision and then tunnelled through
a protective spring that was anchored to the parietal bones using
two stainless steel screws and a self-curing dental acrylic.
Following recovery, the animals were housed in individual cages
in the ABS room. The end of the protective spring was attached
to a mechanical swivel that rotated through 3608 in a horizontal
plane and 1808 through a vertical plane allowing the rats toJournal of Endocrinology (2008) 196, 323–330maximise freedom of movement. The cannulae were flushed
daily with the heparinised saline to maintain patency.Drug treatments
Org 34850 (provided by Organon Laboratories Ltd,
Newhouse, UK) was administered through the s.c. cannula
in a 0.9% saline solution with 5% mulgofen (GAF Ltd,
Manchester, UK), a detergent, which improves solubility, and
the dose of 10 mg/kg dissolved in 1 ml vehicle.
Previous studies indicate that this is the threshold dose to
pass the blood–brain barrier and bind the central GR
(Bachmann et al. 2003).
In our study, we have chosen an administration route
(via an s.c. cannula) that minimises any stress induced in the
rat, by the injection. Due to limited solubility of Org 34850,
the dose used in this study was the largest possible to
administer via this route.
Vehicle controls were injected with 0.9% saline solution
with 5% mulgofen (VEH). Vials containing 40 mg MPL
(Solu-Medrone: MPL as the sodium succinate, Upjohn
Pharmaceuticals, Crawley, UK) were reconstituted with the
supplied diluent. The final dose (500 mg/rat) was administered in
heparin–saline to achieve a total injection volume of 0.1 ml/rat
and it was injected via the jugular cannula over a 30-s time
interval; the control group received an injection of 0.1 ml
heparin–saline (SAL). Both s.c. and i.v. injections were followed
by the injection of 0.2 ml heparin–saline to flush out the cannula
and ensure that the entire volume of drug had been received by
the animal.Experimental procedures
Four experimental groups were used: VEH–SAL, Org
34850–SAL, VEH–MPL and Org 34850–MPL. For each
group, eight animals underwent surgery and were then
connected to the ABS. However, due to an excessive number
of missing samples (O10%), for part of the time period analysed,
between one and three animals from each group were excluded
from the study. The experiments were performed during the late
light phasewhenbasal levels of corticosterone are elevated. Blood
sampling started at 1530. After 1 h basal sample collection, rats
were injected with either Org 34850 or VEH. Thirty min later,
rats from both VEH and Org 34850 were injected with either
MPL or SAL.
The time domain of the two treatments was based on
unpublished data showing that, in mouse, the half-life of Org
34850 (10 mg/kg, s.c.) is 4.5 h and it reaches maximum
plasma concentrations within 30 min of injection (unpub-
lished observations from the manufacturer).
The dynamics of the fast non-genomic response of
corticosterone to MPL, and its modulation by Org 34850,
were examined by rapid sampling over a period of 5.5 h
starting at 1530, with samples collected every 5 min. Org
34850 or VEH were injected at 1630, 30 min before MPL or
SAL administration. To investigate the delayed inhibitionwww.endocrinology-journals.org
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was carried out every 10 min until 0700 of the following day.
At the end of the sampling period, rats were overdosed with
0.5 ml Euthatal (200 mg/ml sodium pentobarbital; Merial,
Harlow, UK). Blood samples were processed for cortico-
sterone RIA as described below.Blood collection and corticosterone measurements
For collection of blood samples, animals were attached to the
(ABS) system as previously described (Clark et al. 1986, Windle
et al. 1997). Blood samples were partially diluted by the ABS so
that each blood sample consisted of 37.7 ml blood diluted in a
ratio of 1:5 in heparinised saline. The corticosterone levels were
measured by RIA. For the assay, 50 ml each blood sample was
further diluted into 50 ml of a citrate buffer (pH 3.0). The
samples were processed in duplicate and incubated overnight at
4 8C with 50 ml 125I corticosterone tracer (Oxford Bio
Innovation DSL Ltd, Oxford, UK) and 50 ml rabbit anti-rat
corticosterone primary antibody (kindly donated by G Makara,
Hungary). On day 2, a charcoal/dextran solution was added to
the samples, which were then centrifuged (15 min, 3120 g,
4 8C) and aspirated before being loaded onto a gamma counter.
Intra- and inter-assay coefficients of variation of the cortico-
sterone assay were 16.65 and 13.30% respectively. The detection
limit of the corticosterone assay was 0.09 ng/ml.Statistical analysis
All statistical analyses were performed using SPSS 11.5 for
Windows (SPSS Inc., Chicago, IL, USA). Data are expressed as
mean (Fig. 1A), meanGS.E.M. (Figs 1B and 2) or individual
blood corticosterone secretion profiles within each groupVEH - SAL100
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Figure 1 Effect of Org 34850 on MPL-induced corticosterone secretion
methylprednisolone (MPL, 500 mg, i.v.) or saline (SAL, 0.1 ml, i.v.), 30
vehicle (VEH, 5% mulgofen in saline, 0.1 ml/kg, s.c). Blood samples
every 5 min (1530–2055 h) or 10 min (2100–0650 h; nZfive to eight p
arrow indicates MPL or SAL injection and grey bar indicates darkness p
value (as % of VEH–SAL) of blood corticosterone levels shown in A an
Org 34850 (1630–1644 h), post-MPL1 (1700–2055 h), post-MPL2 (21
VEH–MPL compared with VEH–SAL; bP!0.0001 for Org 34850–MPL
compared with VEH–MPL.
www.endocrinology-journals.org(VEH–SAL, Org 34850–SAL, VEH–MPL and Org 34850–
MPL; Fig. 3). Based on the diurnal pattern of corticosterone
secretion and the effect of MPL on corticosterone secretion,
corticosterone profiles were divided into different time periods:
basal (1530–1625 h); post-Org 34850 (1630–1655 h),
post-MPL1 (1700–2055 h), post-MPL2 (2100–0250 h) and
post-MPL 3 (0300–0650 h). The data generated during each
time period were analysed separately. To investigate the effect of
MPL and Org 34850 administration on corticosterone
secretion, the area under the curve (AUC; nanogram of
corticosterone) for each experimental group was analysed. In
the presence of a significant effect of either MPL or Org 34850
on AUC at any of the time frame analysed, the hormone profile
for each animal was analysed for variation in pulse characteristics
(mean daily corticosterone concentration and the number,
height and frequency of corticosterone pulses) using the
PULSAR algorithm (Merriam & Wachter 1982). For the
PULSAR algorithm, the following G-values were employed:
G1Z5,G2Z3,G3Z2,G4Z1.5 andG5Z0.8, together with a
peak splitting parameter of 5 (S.D. units). These values were
obtained from visual inspection of the data, as recommended
(Windle et al. 1998). AUC, single time points and PULSAR
parameters were analysed using ANOVA; post hoc analysis
examined the differences between groups using Fisher’s least
significant difference test. The level of significance was set
at P%0.05.Results
Corticosterone profiles were divided into different time periods
shown in Fig. 1A: basal (1530–1625 h); post-Org 34850 (1630–
1655 h), post-MPL1 (rapid non-genomic time domain, 1700–
2055 h), post-MPL2 (delayed genomic domain, 2100–0250 h)-MPL3
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were collected using an automated blood sampling system (ABS)
er group). Black arrow indicates Org 52186 or VEH injection; grey
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Figure 2 Magnification of Fig. 1A showing the effect of Org 34850
on MPL-induced rapid corticosterone secretion decrease (time
frame shown: 1530–2055 h). Blood samples were collected using
an automated blood sampling system (ABS) every 5 min. Black
arrow indicates Org 52186 or VEH injection; grey arrow indicates
MPL or SAL injection and grey bar indicates darkness period (1915–
2100 h). aP!0.001 for VEH–MPL compared with VEH–SAL;
bP!0.001 for Org 34850–MPL compared with Org 34850–SAL.
Figure 3 Examples of individual 15.5-h corticosterone profiles of
methylprednisolone (MPL, 500 mg, i.v., C and D) 30 min prior to acute
s.c., A and C) or Org 34850 (10 mg/kg, s.c., B and D). Blood samples
every 5 min (1530–2055 h) or 10 min (2100–0650 h). Black arrows in
SAL injection and grey bars indicate darkness period (1915–0515 h).
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Journal of Endocrinology (2008) 196, 323–330and post-MPL 3 (diurnal through, 0300–0650 h). The choice of
the time frames for the analysis of corticosterone secretion with
the four experimental groups is based on the experimental
design of the study (basal and post-Org 34850), on the pattern
and mechanism of effect of MPL (post-MPL1 and post-MPL2)
and on the diurnal hormonevariations (post-MPL3). There was
no significant difference in basal corticosterone secretion (basal,
1530–1625 h) among the four experimental groups (Fig. 1B).
Effect of Org 34850 on corticosterone secretion
As already shown in a recent study (Spiga et al. 2007), there
was no significant effect of Org 34850, alone, on
corticosterone secretion or on any of the parameters analysed
to investigate corticosterone pulsatility pattern, at any of the
time periods analysed (Fig. 1B).
Effect of Org 34850 on rapid non-genomic corticosterone response
to MPL
The rapid non-genomic effect of MPL administration
on corticosterone secretion was analysed over a 4-h periodrats injected with either saline (SAL, 0.1 ml, i.v., A and B) or
administration of vehicle (VEH, 5% mulgofen in saline, 0.1 ml/kg,
were collected using an automated blood sampling system (ABS)
dicate Org 34850 or VEH injection; grey arrows indicate MPL or
www.endocrinology-journals.org
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ANOVA revealed that there was a significant effect of i.v.
injection of MPL on corticosterone secretion (AUC,
F(3,28)Z26 159, P!0.0001; Fig. 1B) in both rats treated
with VEH (PZ0.0001) and Org 34850 (P!0.0001), when
compared with rats from the same group but treated with SAL.
No difference between rats treated with VEH or Org 34850,
followed by MPL, was found (PZ0.602). In both VEH- and
Org 34850-treated animals, the onset of effect of MPL was
evident within 25 min of MPL injection and its inhibitory
effect persisted for almost 4 h (Fig. 2). The decrease in
corticosterone secretion induced by MPL in both VEH and
Org 34850 groups was characterised by changes in the corti-
costerone pulsatility pattern (Table 1). An analysis of corti-
costerone profile using the PULSAR algorithm revealed that
both VEH and Org 34850 animals treated with MPL showed a
decreased mean corticosterone concentration (P!0.0001 for
both VEH- and Org 34850-treated groups), reduced number
and frequency of the pulses (P!0.0005 and P!0.005
respectively for VEH- and Org 34850-treated groups).Effect of Org 34850 on delayed genomic corticosterone response
to MPL
Examples of individual 15.5-h corticosterone profiles of rats
injected with either SAL or MPL, 30 min prior to acute
administration of VEH or Org 34850 are shown in Fig. 3.
The onset of the delayed effect of MPL on corticosterone
secretion was determinate based on the results of ANOVA
analysis during the rapid non-genomic time domain showing
a recovery, from MPL effect, for corticosterone secretion after
4 h of MPL administration (2100 h). During the post-MPL2
time period (2100–0250 h), a single injection of Org 34850
had no effect on corticosterone basal secretion compared with
rats injected with VEH followed by SAL (Fig. 3A and B). In
rats treated with VEH, although failing to reach statistical
significance, there was a trend for MPL to reduce
corticosterone secretion during the post-MPL2 time frame,
compared with VEH animals treated with SAL
(F(3,27)Z3.63, PZ0.121; Fig. 3A–C). During the same
time frame, there was a significant increase in corticosteroneTable 1 MeanGS.E.M. of PULSAR parameter measurements of vehicle–s
and Org 34850–MPL rats during the post-MPL1 phase (1700–2055 h). R
saline, 0.1 ml, s.c.) or Org 34850 (10 mg/kg, s.c.) 30 min prior to inject
500 mg/0.1ml, i.v). During the post-MPL1 phase (1700–2050 h), rats inj
reduced corticosterone concentration, reduced number of pulses and re
Corticosterone
concentration (ng/ml) Number of p
VEH–SAL 34.23G4.9 3.8G0.3
Org 34850–SAL 40.85G3.6 3.5G0.4
VEH–MPL 9.11G1.4† 1.5G0.3*
Org 34850–MPL 10.84G1.6§ 1.7G0.2‡
*P!0.0005, †P!0.0001 compared with VEH–SAL; ‡P!0.005, §P!0.0001 comp
www.endocrinology-journals.orgsecretion in Org 34850–MPL compared with VEH–MPL
(PZ0.003; Figs 1B and 3D). We used PULSAR to analyse
the effects of Org 34850 and MPL on corticosterone secretion
pattern (Table 2). For all the parameters analysed, no
significant difference between VEH–SAL- and VEH–MPL-
treated animals was observed. However, Org 34850–MPL-
treated animals showed a significantly increased mean blood
corticosterone compared with VEH–MPL (F(3,27)Z3.100,
PZ0.006). There was also no significant difference in the
mean number, mean height or frequency of corticosterone
pulses between Org 34850–MPL- and VEH–MPL-treated
groups. No differences in corticosterone secretion among the
four experimental groups were found during the post-MPL3
time frame (Fig. 1B).Discussion
We have recently shown that administration of 500 mg MPL
given i.v. partially inhibits the stress-induced increase of
corticosterone secretion. This effect was evident within
75 min of MPL administration and 60 min of onset of the
stressor (Spiga et al. 2007). This time course is within the time
domain of both the rapid non-genomic mechanism of
glucocorticoids and the more classic genomic mechanism,
mediated by translocation of cytoplasmatic GRs into the
nucleus. Interestingly, the effect of MPL on stress-induced
corticosterone secretion was completely blocked by acute
pretreatment with Org 34850 (at the same dose used in the
present study). This suggests that the effect of MPL on
stress-induced corticosterone release, which may be by a
non-genomic mechanism, is mediated by the activation of GR.
In the present study, we show that the same acute dose of
MPL (500 mg), injected at the time of expected diurnal peak
of corticosterone secretion in the evening (1700 h), induces a
rapid decrease in corticosterone secretion. Our results are
consistent with a previous study where higher doses of MPL
(5 and 500 mg/kg) were shown to rapidly reduce cortico-
sterone secretion (Boudinot & Jusko 1986). In our study,
the onset of effect of MPL on corticosterone secretion was
evident within 25 min of MPL administration, suggesting thealine (VEH–SAL), Org 34850–SAL, VEH–methylprednisolone (MPL)
ats were injected with either vehicle (VEH, 5% mulgofen in 0.9%
ion with saline (SAL, 0.1 ml, i.v.) or methylprednisolone (MPL,
ected with MPL, pretreated with either VEH or Org 34850 showed
duced pulse frequency, compared with rats treated with SAL
ulses Pulse height (ng/ml) Pulse frequency (pulse/h)
66.84G7.3 0.97G0.05
71.27G5.9 0.89G0.10
58.15G6.2 0.38G0.07*
61.86G12.7 0.42G0.05‡
ared with Org 34850–SAL.
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Table 2 MeanGS.E.M. of PULSAR parameter measurements of VEH–SAL, Org 34850–SAL, VEH–MPL and Org 34850–MPL rats during the
post-MPL2 phase (2100–0250 h). Rats were injected with either vehicle (VEH, 5% mulgofen in 0.9% saline, 0.1 ml, s.c.) or Org 34850
(10 mg/kg, s.c.) 30 min prior to injection with saline (SAL, 0.1 ml, i.v.) or methylprednisolone (MPL, 500 mg/0.1ml, i.v.). During the peak
phase (2100–0250 h), rats injected with MPL and pretreated with Org 34850 showed increased corticosterone concentration compared with
rats pretreated with VEH. No difference in any other parameter analysed was found among the four experimental groups
Corticosterone
concentration (ng/ml) Number of pulses Pulse height (ng/ml) Pulse frequency (pulse/h)
VEH–SAL 20.4G2.3 2.8G0.3 41.9G3.0 0.47G0.05
Org 34850–SAL 22.6G1.2 2.6G0.6 47.7G2.6 0.43G0.10
VEH–MPL 14.1G1.1 1.8G0.4 33.4G5.9 0.31G0.07
Org 34850–MPL 26.9G4.9* 3.1G0.5 59.2G11.7 0.52G0.08
*P!0.05 compared with VEH–MPL.
F SPIGA and others . GR antagonist and negative feedback328activation of a non-genomic mechanism to suppress HPA axis
activity. However, acute pretreatment with the glucocorticoid
antagonist Org 34850 was unable to antagonise the effect of
MPL, suggesting a mechanism that does not involve a
genomic mechanism following GR activation.
There is an electrophysiological evidence in guinea-pig
ganglion neurons for rapid effects of cortisol on cell
membranes, which can be reversed by the glucocorticoid
antagonist RU 38486 (Hua & Chen 1989), and in vitro data
suggesting involvement of GR activation in fast, intermediate
and delayed feedback (Dayanithi & Antoni 1989). Our results,
however, are more consistent with previous in vivo data which
show that rapid negative feedback effects of exogenous
glucocorticoids can be demonstrated on CRF-induced
ACTH secretion in rats, and that these were not affected by
the acute administration of the glucocorticoid antagonist RU
486 (Hinz & Hirschelmann 2000).
MPL is a synthetic glucocorticoid that binds to both GR and
MR (Grossmann et al. 2004). It is therefore possible that MPL-
induced rapid corticosterone secretion inhibition could be
mediated by the activation of MR. Indeed, we have recently
found that the MR antagonist canrenoate can activate the HPA
axis (Atkinson et al.) and can also antagonise the rapid feedback
induced by MPL (Atkinson et al. unpublished). These data also
fit with another report where electrophysiological evidence for
rapid MR-mediated responses are described (Karst et al. 2005).
This is further supported by evidence that, in both rats and man,
MRs are also activated throughout the 24 h period both at the
circadian peak of corticosterone secretion, and at the circadian
trough (Bradbury et al. 1994, Spencer et al. 1998, Young et al.
2003). There is also recent data using a novel prednisolone
suppression test in man that suggest an involvement of MR in
dysfunctional feedback mechanism in depressed patients
(Juruena et al. 2006).
Due to the unstable nature of the ACTH peptide and the
relatively large volumes of blood required for the ACTH
measurement, the blood collected in this study by the
sampling system could not be used to ascertain ACTH levels
throughout the entire sampling period. Therefore, we have
no evidence that MPL will reduce ACTH secretion within
the same rapid domain as corticosterone. In light of this, anJournal of Endocrinology (2008) 196, 323–330involvement of the adrenal glands as site of effect of MPL
could not be excluded.
The activity of the HPA axis is characterised by an
endogenous diurnal rhythm ( Jasper & Engeland 1991). Cortisol
in man, and corticosterone in rodents, is released in a pulsatile
manner throughout the 24-h period and it is the variation in the
amplitude and frequency of these pulses that determines the
diurnal rhythm (Windle et al. 1998). An acute administration of
Org 34850 to rats did not alter the secretory characteristics of
corticosterone secretion in keeping with our previous findings.
Indeed, an acute administration of Org 34850 has no effect on
corticosterone diurnal rhythm, whereas sub-chronic (5 days)
treatment with the same drug induces an increase in the
corticosterone secretion over the 24-h cycle, with an increased
number of pulses, pulse height and frequency.
Here we found that, in the rapid feedback time domain, the
reduction in corticosterone secretion by acute administration
of MPL was also characterised by a reduction in pulsatility that
lasted for 4 h. Indeed, following MPL administration, rats
treated with vehicle or with Org 34850 showed a reduction in
the number and frequency of corticosterone pulses.
In the delayed feedback domain we found that Org 34850
significantly increases plasma levels of corticosterone in rats that
were subsequently injected with MPL. Moreover, analysis of
corticosterone profiles using PULSAR algorithm revealed
significantly greater levels of corticosterone in rats injected
with MPL and pretreated with Org 34850 compared with rats
injected with MPL but pretreated with vehicle only. No effect
on pulse number, height or frequency was found between the
two groups with the delayed feedback time domain.
Unlike the effects of MPL in the rapid feedback time
domain, which is unaffected by the presence of the GR
antagonist, the effects in the delayed time domain do appear to
be mediated through GR.
It is unclear whether the rapid non-genomic and the
delayed genomic effect of glucocorticoids are mediated by
central structures involved in HPA axis modulation, such as
the prefrontal cortex, hippocampus, amygdala and para-
ventricular nucleus or by the pituitary gland or a combination
of these. There is also some evidence that MPL is only poorly
able to penetrate the blood–brain barrier as a result of thewww.endocrinology-journals.org
GR antagonist and negative feedback . F SPIGA and others 329P-glycoprotein pump (Koszdin et al. 2000). Interestingly, we
also have data that the synthetic glucocorticoid agonist
dexamethasone, which is an excellent substrate for the
P-glycoprotein pump, is also able to induce a rapid decrease
in corticosterone secretion in rats following i.v. injection
(unpublished observations; Andrews). These data would
support the idea that the rapid effect of MPL is at a pituitary
rather than at a central level. It should be noted that there is
evidence for the presence of MR as well as GR within the
anterior pituitary (De Kloet et al. 1975, De Nicola et al. 1981,
Reul et al. 1990). The physiological role of this pituitary MR
remains unknown, although MR in the hippocampus and in
the anterior pituitary appears to be differentially regulated by
glucocorticoids (Hugin-Flores et al. 2004). Additional studies
with site-specific administration of GR antagonists would be
necessary to investigate this further.
In summary, our data suggest that the effect of MPL on
fast/intermediate feedback is via a non-genomic mechanism,
which is not mediated through GR, whereas delayed
feedback can be antagonised by the selective glucocorticoid
antagonist Org 34850.Acknowledgements
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